SYN Synthetic Biologics Inc

Price (delayed)

$1.56

Market cap

$24.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.21

Enterprise value

-$25.95M

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's ...

Highlights
Synthetic Biologics's EPS has soared by 72% YoY but it has decreased by 6% from the previous quarter
The debt has increased by 4.7% year-on-year but it has declined by 4.3% since the previous quarter
The quick ratio has plunged by 89% YoY and by 24% from the previous quarter
The net income has shrunk by 79% YoY and by 11% QoQ

Key stats

What are the main financial stats of SYN
Market
Shares outstanding
15.84M
Market cap
$24.72M
Enterprise value
-$25.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.78M
EBITDA
-$17.71M
Free cash flow
-$16.24M
Per share
EPS
-$1.21
Free cash flow per share
-$1.02
Book value per share
$3.89
Revenue per share
$0
TBVPS
$4.87
Balance sheet
Total assets
$82.33M
Total liabilities
$20.66M
Debt
$1.7M
Equity
$61.67M
Working capital
$41.62M
Liquidity
Debt to equity
0.03
Current ratio
4.14
Quick ratio
3.95
Net debt/EBITDA
2.86
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-22.4%
Return on equity
-26.5%
Return on invested capital
-216.6%
Return on capital employed
-25.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SYN stock price

How has the Synthetic Biologics stock price performed over time
Intraday
1.96%
1 week
9.86%
1 month
-4.29%
1 year
-64.06%
YTD
-42.69%
QTD
-26.86%

Financial performance

How have Synthetic Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.78M
Net income
-$17.78M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 79% YoY and by 11% QoQ
The company's operating income has shrunk by 78% YoY and by 11% QoQ

Growth

What is Synthetic Biologics's growth rate over time

Valuation

What is Synthetic Biologics stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Synthetic Biologics's EPS has soared by 72% YoY but it has decreased by 6% from the previous quarter
SYN's P/B is 35% below its last 4 quarters average of 0.6
SYN's equity is down by 19% YoY and by 9% from the previous quarter

Efficiency

How efficient is Synthetic Biologics business performance
The return on invested capital has surged by 93% year-on-year and by 25% since the previous quarter
The ROA has soared by 53% YoY but it has contracted by 9% from the previous quarter
The ROE has soared by 53% YoY but it is down by 17% QoQ

Dividends

What is SYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYN.

Financial health

How did Synthetic Biologics financials performed over time
The quick ratio has plunged by 89% YoY and by 24% from the previous quarter
Synthetic Biologics's current ratio has plunged by 89% YoY and by 24% from the previous quarter
The debt is 97% smaller than the equity
The debt to equity has soared by 50% YoY
SYN's equity is down by 19% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.